tirzepatide laseraway — Provider-Supervised GLP-1 / GIP Program LASERAWAY - Updated July 2026

RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)

Our next investment can be in your own innovative startup

A., Wilkaniec, A

Both receptor systems engage

RDA, Recommended Daily Allowance

As a result, affected individuals may experience: Severe abdominal pain Abdominal bloating Vomiting Nausea Loss of appetite Acid reflux Weight loss Malnutrition Ozempic Linked to Serious Eye Condition and Vision Changes A study published by JAMA Ophthalmology in July 2024 determined that user of semaglutide drugs like Ozempic face an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION)